A specialty as diverse as urologic nursing requires comprehensive educational offerings that keep nurses up to date in the varied practice areas. The Society of Urologic Nurses and Associates (SUNA) will continue to show its commitment to excellence in clinical practice by hosting its 40th Annual Conference, October 2-5, 2009, at the Hyatt Regency Chicago, in Chicago, IL. The conference is ideal for nurses, physician's assistants, technicians, medical assistants, office personnel, industry representatives and physicians. Educational sessions are organized in specialized tracks, and attendees will be able to concentrate on their special interest or practice area.
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced that Feraheme ™ (ferumoxytol) Injection is now available for commercial sale in the United States. Feraheme is an intravenous (IV) iron replacement therapy for the treatment of iron deficiency anemia in adult patients with chronic kidney disease. Feraheme can provide patients with a 1 gram therapeutic course of iron in two 510 mg IV injections administered as quickly as 17 seconds each, within one week. Feraheme was approved by the U.S. Food and Drug Administration on June 30, 2009. The Company will be marketing and selling Feraheme in the U.S. through its commercial organization consisting of approximately 150 seasoned professionals, including an 80-person specialized sales force, an experienced account management and reimbursement team, and a contract nurse team.
Physician-scientists from NewYork-Presbyterian Hospital/Weill Cornell Medical Center believe that a heightened level a certain growth factor in the blood may explain why blacks have a greater prevalence of hypertension and kidney disease compared to whites. Results from a new study are the first to show that an elevated level of a protein, called transforming growth factor b1 (TGF-b1), raises the risk of hypertension and renal disease in humans. African Americans constitute about 32 percent of all patients treated for kidney failure in the U.S. and are four times more likely to develop renal disease than whites, according to the National Institutes of Health's U.
The U.S. Food and Drug Administration said that it will require manufacturers of some immunosuppressant drugs used in kidney (renal) transplantation to update their labeling to reflect an increased risk of infections. The required label changes affect the following immunosuppressant drugs used to help prevent rejection of transplanted organs: - Rapamune (sirolimus) - Sandimmune (cyclosporine) and cyclosporine generics - Neoral (cyclosporine modified), and generics - Cellcept (mycophenolate mofetil) and generics - Myfortic (mycophenolic acid) The FDA is requiring the labeling changes based on its review of reported adverse events. The labeling changes must reflect the reported increased risk for opportunistic infections, including activation of latent viral infections.
A London surgeon is pioneering a new way to remove abdominal organs through the belly button using an approach called single incision laparoscopic surgery (SILS) which requires only a 10 mm cut in the navel to allow entry of a camera and all the surgical instruments and through which organs like the appendix and gall bladder can be removed. Imperial College Healthcare NHS Trust consultant surgeon Paraskevas Paraskeva, who also lectures at Imperial College London, is the first UK surgeon to use SILS to remove an appendix and a gall bladder. Before SILS the organs were removed using three cuts in the torso, as well as the belly button, which leaves the patient with abdominal scars.
Effects Of Once-Daily Tadalafil On Erectile Function In Men With Erectile Dysfunction And Signs And Symptoms Of Benign Prostatic Hyperplasia
UroToday.com - Men with benign prostatic hyperplasia (BPH) often suffer from lower urinary tract symptoms (LUTS; BPH-LUTS) such as urinary frequency, urgency, intermittency, nocturia, straining, incomplete emptying, or weak urinary stream. BPH-LUTS and erectile dysfunction (ED), both highly prevalent conditions in aging men, are frequently associated in the same men, may have common pathophysiological mechanisms, and contribute negatively to quality of life. Phosphodiesterase type 5 (PDE5) isozymes are considered promising targets for drug intervention in the urogenital tract, and the potential use of PDE5 inhibitors as treatment for both BPH LUTS and ED is of clinical interest.